Dosage Regimen for the Treatment of Cancer
OwnerPablo MORENTIN GUTIERREZ, Camila DE ALMEIDA +1inventors
InventorsPablo MORENTIN GUTIERREZ, Camila DE ALMEIDA, Eric Todd GANGL
Life of this patent
Estimating the term…
Abstract
The present specification relates to AZD9833 for use in the treatment of cancer and methods of treatment of cancer involving administration of AZD9833 wherein, in each case, the AZD9833 is administered orally once daily at a dose between 25 mg and 450 mg. AZD9833 may be administered alone or its use may be in combination with an additional anti-cancer agent such as a CDK inhibitor, everolimus or an AKT inhibitor.
Claims28
-28. (canceled)
A method of treating cancer in a human or animal patient in need of such treatment, comprising administering to the patient a compound, or a pharmaceutically acceptable salt thereof, once daily at a dose between 25 mg and 450 mg, wherein the compound is N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine.
An oral pharmaceutical composition comprising between 25 mg and 450 mg of a compound, or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable excipient;
- wherein the compound is N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine.
A kit comprising:
- an oral pharmaceutical composition comprising from 25 mg to 450 mg of N-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient;
- and
- instructions for the use of the composition in the treatment of cancer.
Dependencies are inferred from the claim text.